Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT05557591 |
Title | Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 >= 50% |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | Yes |
Sponsors | Regeneron Pharmaceuticals |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA | ESP | DEU |